RecruitingNCT06314230

Australian Genomics Of Chronic Allograft Dysfunction Study

Sponsor

Western Sydney Local Health District

Enrollment

500 participants

Start Date

Apr 26, 2012

Study Type

OBSERVATIONAL

Conditions

Kidney Transplant; Complications Kidney Transplant Rejection

Summary

The goal of the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a single centre (Westmead Hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant) transplant and tracks the post transplant course. The AUSCAD study aims to generate new knowledge and improve outcomes following kidney transplantation. The primary aim is to determine whether important outcomes (including chronic rejection and graft loss) are correlated with patterns of allograft reactivity, gene expression and susceptibility profiles.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria6

Living or deceased donor kidney transplant candidate.
Biological sex: any
Ages: 18-75 years.
Subject must be able to understand and provide informed consent.
Deceased donor individuals where Research Consent has been obtained from the person consenting to organ donation at the time of organ retrieval.
Identifiable living donors who have received informed consent and have consented to participate in the project.

Exclusion Criteria5

Presensitization in living donor recipients prior to transplantation, as determined by site-specific standards, OR positive cross match according to site specific technique in cadaveric donor recipients.
Recipients of multiple organ transplants, with the exception of kidney/pancreas transplants.
Inability or unwillingness of a participant to give written informed consent or comply with study protocol
High risk populations including pregnant women, children less than 18 years and prisoners will not be included in the study.
Non English speaking potential participants who do not understand the requirements of the study will not be included.

Interested in this trial?

Get notified about updates and connect with the research team.